

**Table S1.** Baseline Characteristics of Participants With or Without Archived M184V/I in the Proviral Resistance Analysis Population (PRAP<sup>a</sup>)

Baseline characteristics	DTG/3TC (N=320)		TAF-based regimen (N=318)	
	M184V/I (N=4)	Wild-type (N=316)	M184V/I (N=3)	Wild-type (N=315)
Age, median (range), y	40.5 (31-61)	40.5 (20-74)	43.0 (28-52)	40.0 (18-73)
Sex, male, n (%)	4 (100)	295 (93)	3 (100)	290 (92)
Race, White, n (%)	4 (100)	253 (80)	2 (67)	242 (77)
HIV-1 subtype, B, n (%)	4 (100)	277 (88)	2 (67)	273 (87)
Region, USA	4 (100)	128 (41)	1 (33)	135 (43)
Baseline third agent class, INSTI, n (%)	3 (75)	249 (79)	3 (100)	250 (79)
Baseline CD4+ count, median (range), cells/mm <sup>3</sup>	750.0 (508-1062)	677.5 (133-1671)	575.0 (416-1075)	725 (119-1810)
Duration of ART before Day 1, median (range), mo	72.5 (50.2-158.3)	34.4 (7.3-201.2)	27.7 (9.3-30.3)	36.4 (7.0-147.4)

ART, antiretroviral therapy; DTG, dolutegravir; INSTI, integrase strand transfer inhibitor; RAM, resistance-associated mutation; TAF tenofovir alafenamide; 3TC, lamivudine.

<sup>a</sup>PRAP is described in the Methods.